The innovative drug has the potential to act as a dual-mode antiviral and anti-inflammatory agent for lung diseases
Celestial Therapeutics’ researchers are actively working on groundbreaking advancements in the field of antivirals, anti-inflammatories, mRNA vaccines, and therapeutics. Their mission is to revolutionise the treatment, prevention, and even eradication of infectious diseases, rare conditions, and various forms of cancer.
The healthcare innovation company has demonstrated scientific expertise and is committed to addressing the significant public health concern posed by Respiratory Syncytial Virus (RSV), a common respiratory virus that affects people of all ages, particularly infants, young children, and older adults. Developing an effective dry powder inhalation product against RSV has the potential to revolutionise the treatment and prevention of this viral infection, improving the lives of countless individuals worldwide.